Orexo
15.58 SEK +2.5%Be the first to follow this company
Orexo develops drugs and digital therapies that meet needs, especially in the area of mental health and diseases related to drug and drug abuse. The products are commercialized by Orexo in the USA or through partners all over the world. The main market is the American market for buprenorphine / naloxone products, where Orexo commercializes the main drug Zubsolv®, for the treatment of opioid dependence. The head office, where research and development work is conducted, is located in Uppsala.
Revenue
638.8M
EBIT %
-17.14 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ORX
Daily low / high price
14.82 / 15.64
SEK
Market cap
540.79M SEK
Turnover
127.85K SEK
Volume
8.3K
Latest videos
Financial calendar
General meeting
2024-04-26
Interim report
2024-05-08
Interim report
2024-07-17
Interim report
2024-11-14
Annual report
2025-02-06
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Novo A/S | 27.8 % | 27.8 % |
Avanza Pension | 6.9 % | 6.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Orexo publishes the Annual and Sustainability Report for 2023
Penser Access by Carnegie: Orexo - Stärka finanser
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools